Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Theranexus, a biopharmaceutical enterprise, specializes in the creation of potential medications for ailments affecting the central nervous system. Their primary investigational compound, THN102, is presently undergoing Phase II clinical evaluation for conditions related to sleep and wake cycles. Furthermore, they are developing THN201 to target neurocognitive challenges associated with Alzheimer's disease, and THN101 for the management of neuropathic discomfort. This company commenced operations in 2013 and is situated in Lyon, France.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, undervalued on P/F
Target Price
The average target price of ALTHX.PA is 5.80 and suggests 74.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to